A Reversal for Affimed N.V. (NASDAQ:AFMD) Is Near. The Stock Has Decrease in Shorts

June 17, 2018 - By Michael Collier

The stock of Affimed N.V. (NASDAQ:AFMD) registered a decrease of 24.35% in short interest. AFMD’s total short interest was 369,800 shares in June as published by FINRA. Its down 24.35% from 488,800 shares, reported previously. With 252,600 shares average volume, it will take short sellers 2 days to cover their AFMD’s short positions. The short interest to Affimed N.V.’s float is 1.46%.

The stock decreased 15.31% or $0.375 during the last trading session, reaching $2.075. About 2.81 million shares traded or 533.01% up from the average. Affimed N.V. (NASDAQ:AFMD) has declined 6.38% since June 17, 2017 and is downtrending. It has underperformed by 18.95% the S&P500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $129.46 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More notable recent Affimed N.V. (NASDAQ:AFMD) news were published by: Benzinga.com which released: “31 Stocks Moving In Thursday’s Mid-Day Session” on June 14, 2018, also Benzinga.com with their article: “Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data” published on June 15, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018. More interesting news about Affimed N.V. (NASDAQ:AFMD) were released by: Nasdaq.com and their article: “Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with …” published on June 15, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Dow Down Over 200 Points; Affimed Shares Plummet” with publication date: June 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: